Introduction
============

Chemerin, also known as tazarotene-induced gene 2 protein (TIG2) and retinoic acid receptor responder 2 (RARRES2), is a 14-kDa chemoattractant protein known to modulate immune system function through its binding to the chemerin receptor ChemR23 ([@bib1]). It is secreted in an inactive form as prochemerin and is activated through cleavage of the C-terminus by inflammatory and coagulation serine proteases. Animal studies indicated visceral adipose tissue, placenta and liver, and to a lesser extent lungs, heart, ovaries, kidneys and pancreas as main anatomical sites of chemerin production ([@bib2], [@bib3]). Chemerin was initially identified as a retinoid-responsive gene present in psoriatic skin lesions in 1997 using differential display ([@bib4]). Ten years later (in 2007) chemerin was re-discovered as a novel adipokine regulating adipogenesis and genes critical in glucose and lipid metabolism of adipocytes ([@bib3]). Subsequent research characterized additional roles of chemerin in diverse biological processes including cell proliferation and differentiation, angiogenesis, renal function and energy metabolism ([@bib3], [@bib5], [@bib6], [@bib7]). Collectively, chemerin could be distinguished as an immune marker acting as a chemoattractant agent promoting the recruitment of immune cells to lymphoid organs and sites of tissue damage and as autocrine/paracrine signaling agent that is involved in several metabolic and cell-developmental processes particularly in adipocytes ([@bib8]). Higher circulating chemerin concentrations have been reported in patients suffering from systemic inflammatory diseases such as Crohn's disease, ulcerative colitis ([@bib9]), liver diseases ([@bib10]), chronic pancreatitis ([@bib11]) and polycystic ovary syndrome ([@bib12]). Cross-sectional studies reported associations between chemerin and biomarkers of inflammation, metabolic parameters and anthropometric measures of adiposity ([@bib13]). However, little is known about the interrelations of chemerin with inflammation-related adipokines. Particularly, there have been no studies based on human population samples.

In summary, recent research has uncovered chemerin as an adipokine implicated in immune, inflammatory and obesity-related pathophysiological conditions. However, no data from large-scale prospective population-based studies exist to support or refute generated hypothesis on chemerin involvement in disease development. Important prerequisite for planning biomarker assessment in a prospective study is the assessment of whether single biomarker measurements, as done in most epidemiological research settings, are stable over time and not affected by biological variability ([@bib14]). So far, the reliability of chemerin as biomarker in human research has not been evaluated. To fill this gap, we aimed to assess the intra-individual reproducibility of plasma chemerin concentrations over a 4-month interval using data from a sample of apparently healthy participants within the European Prospective Investigation into Cancer and Nutrition (EPIC) Potsdam Study. As a secondary aim, we analyzed the cross-sectional association of chemerin with inflammation-related adipokines.

Methods
=======

Study population
----------------

The EPIC-Potsdam Study is part of the multicenter prospective cohort study EPIC, which was designed to investigate the association between nutrition, cancer and other chronic diseases ([@bib15]). In Potsdam, Germany, 27,548 participants (16,644 women aged 35--65 years and 10,904 men aged 40--64) were recruited between 1994 and 1998 ([@bib16]). The present study was based on a randomly selected sample from all participants of the EPIC-Potsdam Study population ([@bib17]). Exclusion criteria included history of heart disease and stroke (myocardial infarction, heart failure, cardiomyopathy and angina pectoris), impaired mobility, current therapy with β-blockers or systolic or diastolic blood pressure above 180 mmHg or 110 mmHg, respectively. Of the initially invited 407 participants, 11 did not respond to the invitation, 176 declined study participation. Twelve participants were additionally excluded due to reported therapy of β-blockers. From the remaining participants, all but one provided blood samples leading to a total sample size of 207 participants (124 women and 83 men). Blood samples were collected on two occasions 4 months apart with the first in the period of October 2007--March 2008 and the second between February and July 2008. Timing of blood collection was, with few exceptions, 08:00--11:00 h, with ca. 10% of participants not being fasted. All participants provided written informed consent and the study procedures were approved by the Ethics Committee of the Medical Association of the State of Brandenburg.

Biomarker measurements
----------------------

On two occasions, four months apart, blood was drawn, the fractions separated and stored at −80°C. With the exception of high-sensitivity C-reactive protein (hsCRP), which was measured in serum, concentrations of chemerin, fatty acid-binding protein 4 (FABP-4), monocyte chemoattractant protein 1 (MCP-1), omentin-1, progranulin and vaspin were measured in EDTA-plasma. All biomarkers were measured with commercially available sandwich enzyme-linked immunosorbent assays (ELISA) (BioVendor, Kassel, Germany) according to the manufacturer's instructions. Repeated samples of each participant were measured in the same analytical batch. Measurements of chemerin and omentin-1 were performed at the Institute of Clinical Chemistry, University Magdeburg. Manufacturer's specified average intra- and inter-assay coefficients of variation (CV) for chemerin were 6.0% and 7.6%, respectively. Inter-assay CV based on our data was 5.9%. Measurements of hsCRP in serum and FABP-4, MCP-1, progranulin and vaspin in plasma were performed in the Department of Clinical Nutrition, German Institute of Human Nutrition Potsdam-Rehbrücke, Germany. The intra- and inter-individual CVs of hsCRP were 5.1% and 6.1%, respectively as reported by the manufacturer. Based on our data, the inter-individual CV was 11.0%. Due to insufficient serum volume, hsCRP could only be measured in a reduced number of participants (*n* = 151). Detailed information on the measurements of plasma FABP-4, MCP-1, omentin-1, progranulin and vaspin concentrations have been reported elsewhere ([@bib18], [@bib19]).

Statistics
----------

Non-normally distributed data were transformed using the natural logarithm in order to allow the application of parametric tests and the calculation of mean concentrations. Non-normality was determined by visual inspection of the histogram and quantile--quantile plot evaluation. Mean chemerin concentrations are presented as geometric means. Strata-specific mean concentrations were calculated for sex, BMI (\<25 kg/m^2^ vs ≥25 kg/m^2^), waist circumference (♂: \<94 cm vs ≥94 cm, ♀: \<80 cm vs ≥80 cm) and inflammatory status represented by hsCRP concentration (below sample median vs above median). A random-effects analysis of variance (ANOVA) with chemerin concentration as dependent variable and study participant as explanatory variable was used to estimate the variance components explained by within-person and between-person differences, respectively. Overall and strata-specific intraclass correlation coefficients (ICCs) were calculated as ratios of between-person variance and total variance (between-person variance + within-person variance).

To compare mean chemerin concentrations between sampling time points and between categories within one sampling time point, paired and unpaired two-sided Student's *t*-tests were applied. In addition to ICCs, reliability was also evaluated by inspection of Bland--Altman plots as a recommended complementing procedure to assess the agreement of two measurements for each participant ([@bib20]). To evaluate interdependence with the individual characteristics, the ICCs were calculated across the above defined strata (sex, BMI, waist circumference and hsCRP levels). Following established cut points, estimated reproducibility is rated as excellent (ICCs ≥0.75), good (ICC: 0.74--0.60), fair (ICC: 0.59--0.40) or poor (ICCs \<0.40). In sensitivity analyses, ICCs were calculated after excluding participants with extreme chemerin measurement values (values within 1st or above 99th percentile) and non-fasting participants at blood sampling. Using linear regression, we examined the influence of time of day at blood draw taking into account age, sex, fasting status at blood draw and BMI.

Correlation of chemerin with anthropometric measures of adiposity (BMI and waist circumference) and selected biomarkers, including hsCRP, FABP-4, MCP-1, omentin-1, progranulin and vaspin were evaluated using Spearman partial correlation analyses adjusted for age and sex. Correlation analyses with the biomarkers were additionally adjusted for BMI. Fisher's *z* transformation was used to produce 95% confidence intervals for each correlation coefficient. In linear regression analyses, we modeled anthropometric measures and biomarkers as predictors of chemerin concentrations to estimate the explained variance represented by the adjusted coefficient of determination (adjusted *R*^2^). Adjusted *R*^2^ takes into account the number of predictors in the model, which automatically would increase the explained variance with every additionally included variable without actually having a predictive value. In correlation and regression analyses anthropometric indices and biomarker concentrations of the first (baseline) measurement were used as these did not substantially differ from the second measurement. We also calculated the degree of attenuation of hypothetical relative risk estimates (RR) that could arise due to biological variability of chemerin based on the following formula: . All statistical analyses were performed in SAS (version 9.4, Enterprise Guide 6.1, SAS Institute Inc., Cary, NC, USA).

Results
=======

[Table 1](#tbl1){ref-type="table"} presents baseline characteristics of the study population. The mean ([s.d.]{.smallcaps}) age of the participants was 56.5 (4.2) years. On average, participants had a BMI of 26.0 (4.0) kg/m^2^ and a WC of 93.0 (12.8) cm. BMI and waist circumference measurements were stable over the period of 4 months (ICC = 0.99, ICC = 0.98, respectively). Table 1Baseline characteristics of the study population, overall and by sex^A^.**All participants** (*n* = 207)**Men** (*n* = 83)**Women** (*n* = 124)Age (years)56.5 (4.2)58.0 (3.1)55.4 (4.5) Range44.8--63.951.5--63.744.83--63.9BMI (kg/m^2^)26.5 (4.0)27.6 (3.5)25.8 (4.1) Range19.1--41.719.8--37.019.1--41.7Waist circumference (cm)93.0 (12.8)101.7 (10.3)87.1 (10.7) Range68.3--126.479.3--126.468.3--115.8Non-fasting (%)10138Chemerin (ng/mL)159 (137, 186)162 (139, 186)156 (135, 188) Range82.4--28382.4--283105--278hsCRP (μg/mL)^B^1.24 (0.65, 2.45)1.52 (0.72, 2.90)1.10 (0.58, 2.21) Range0.14--13.40.14--12.90.16--13.4FABP-4 (ng/mL)22.8 (17.5, 27.6)19.7 (15.1, 23.4)25.4 (20.8, 30.4) Range0.25--55.08.0--54.90.25--55.0MCP-1 (ng/mL)0.44 (0.35, 0.53)0.43 (0.36, 0.51)0.44 (0.34, 0.54) Range0.15--1.620.19--1.320.15--1.62Omentin-1 (ng/mL)382 (313, 467)362 (306, 433)396 (319, 492) Range99.4--94599.4--945163--789Progranulin (pg/mL)30.8 (26.35, 36.14)32.8 (26.3, 38.4)30.2 (26.4, 34.6) Range0.40--61.00.40--61.00.45--59.5Vaspin (ng/mL)0.20 (0.14, 0.32)0.18 (0.12, 0.22)0.24 (0.15, 0.36) Range0.03--7.080.03--5.610.04--7.08[^1][^2]

[Table 2](#tbl2){ref-type="table"} presents overall and strata-specific chemerin concentrations and ICCs. Chemerin concentrations were higher in participants with higher BMI (≥25 kg/m^2^), WC (♀: ≥80 cm, ♂: ≥94 cm) and hsCRP (above 1.3 μg/mL) compared to lower strata. The overall ICC of a 4-month period was 0.72 (95%-CI: 0.65, 0.78), indicating 'good' reliability. Strata-specific ICCs did not substantially differ between the sexes and according to strata of BMI, WC and hsCRP levels staying within the interval of 'good' reliability ([Table 2](#tbl2){ref-type="table"}). Information from the Bland--Altman plots ([Fig. 1](#fig1){ref-type="fig"}) essentially confirmed a good agreement and symmetric distribution of the measurements. Using the overall ICC (0.72), hypothetical true risk estimates would be attenuated by ca. 11% (RR~true~ = 1.5), 23% (RR~true~ = 2.5) and 30% (RR~true~ = 3.5) due to intra-individual chemerin variability. Sensitivity analyses showed a slight improvement of the ICC (0.77 (0.71, 0.82)) when participants with extreme (within 1st or above 99th percentile) chemerin concentrations were excluded. The ICC did not change when non-fasted participants were excluded, while in non-fasted participants the ICC was slightly reduced (0.70 (0.48, 0.84)). Linear regression analyses of chemerin concentrations according to time of day showed no effect at both sampling time points (beta coefficients corresponding to change of chemerin concentration (ng/mL) per hour of day (95% CI): 1st: 0.73 (−5.94; 7.40), 2nd: 2.69 (−4.41; 9.78)). Figure 1Bland--Altman plot. Agreement of repeated measurements (*y*-axis) in relation to average concentrations (*x*-axis) for each individual (*n* = 207). Agreement was calculated as difference between the two measurements (t2--t1) for each individual. 95% confidence bounds represent the expected range of differences based on the average difference. Values of one participant were excluded from the figure, but not from calculation of mean difference and 95% CI, to improve the legibility of the figure. Values for this participant were individual difference = 297.7 (ng/mL), average individual concentration = 258.5 (ng/mL). Table 2Overall and stratified concentrations (geometric mean (95%-CI)) in ng/mL for measurements taken 4 months apart and ICCs.***N*First measurementSecond measurement*P* difference**^A^**ICC^C^**All207161.0 (156.0, 166.0)155.6 (150.5, 160.9)0.0050.72 (0.65, 0.78)Sex Men83163.4 (155.1, 172.0)155.5 (147.6, 163.8)0.010.73 (0.61, 0.82) Women124159.4 (153.3, 165.7)155.7 (149.1, 162.7)0.140.72 (0.63, 0.80) *P* difference^B^0.450.97BMI \<25 kg/m^2^81145.8 (139.3, 152.7)139.3 (133.2, 145.7)0.0040.75 (0.64, 0.83) ≥25 kg/m^2^126171.5 (165.1, 178.2)167.1 (160.2, 174.3)0.130.64 (0.54, 0.74) *P* difference^B^\<0.001\<0.001Waist circumference ♀: \<80 cm, ♂: \<94 cm56141.2 (134.7, 148.0)136.5 (129.6, 143.9)0.040.78 (0.65, 0.86) ♀: ≥80 cm, ♂: ≥94 cm151169.0 (163.0, 175.2)163.4 (157.2, 169.8)0.030.66 (0.57, 0.75) *P* difference^B^\<0.001\<0.001hsCRP^D^ Below median70149.8 (143.2, 156.8)145.1 (138.1, 152.5)0.040.78 (0.67, 0.86) Above median71170.3 (161.3, 179.7)164.3 (155.3, 173.9)0.050.78 (0.68, 0.86) *P* difference^B^\<0.001\<0.001[^3]

We observed higher chemerin concentrations in obese participants as compared to non-obese ([Table 2](#tbl2){ref-type="table"}). Chemerin concentrations were also positively correlated with BMI (rho = 0.35 (95%-CI: 0.22, 0.47)) and waist circumference (0.37 (0.24, 0.48)). However, when adjusting for hsCRP and adipokines the correlations were greatly attenuated (BMI: 0.12 (−0.05, 0.28), waist circumference: 0.16 (0.00, 0.32)). Chemerin showed a correlation with hsCRP (0.26 (0.10, 0.41)), as well as with the adipokines FABP-4 (0.28 (0.12, 0.42)) and progranulin (0.23 (0.07, 0.38)), when adjusted for age, sex and BMI. No correlation was observed with MCP-1, omentin-1 and vaspin. Mutual adjustments did not essentially change the correlations of the biomarkers with chemerin ([Fig. 2](#fig2){ref-type="fig"}). Linear regression analyses showed that the addition of hsCRP to a model including BMI and waist circumference (adjusted *R*^2^ = 14.6%) increased explained variance of chemerin concentrations by 7.0 percentage points ([Fig. 3](#fig3){ref-type="fig"}). Additionally including progranulin or FABP-4 produced even further increase in explained variance by 1.6 and 4.9 percentage points indicating FABP-4 and progranulin as independent predictors of chemerin concentrations. A model comprising all mentioned variables (BMI, waist circumference, hsCRP, progranulin and FABP-4) resulted in 28.0% explained variance. Figure 2Spearman correlation coefficients (95% CI) for chemerin with inflammation-related biomarkers adjusted for age, sex, BMI and mutually with remaining biomarkers. Analysis based on *n* = 151 due to insufficient serum volume for hsCRP measurements. 95% CI calculated using Fisher's *z* transformation. FABP-4, fatty acid-binding protein-4; hsCRP, high-sensitivity C-reactive protein; MCP-1, monocyte chemoattractant protein 1. Figure 3Percentages of explained variance (represented by adjusted *R*^2^) of chemerin concentrations. Adjusted *R*^2^ was derived from linear regression models with chemerin concentrations as dependent variable and anthropometric measures and biomarker concentrations as independent variables. Models are based on data of participants with available hsCRP measurements (*n* = 151). Adjusted *R*^2^, adjusted coefficient of determination; FABP-4, fatty acid-binding protein-4; hsCRP, high-sensitivity C-reactive protein; WC, waist circumference.

Discussion
==========

Here, we provide first results for the reliability of chemerin. Our data suggest that chemerin measurements have a good reproducibility over a 4-month time period indicating that single chemerin measurements in prospective studies would be suitable and informative for research. In addition, we report for the first time on interrelations between chemerin and inflammation-related adipokines. Taken together, the data support further prospective studies aimed at improving our understanding of chemerin actions in humans and its potential role in the pathogenesis of inflammation-related diseases and conditions.

Chemerin has been proposed to play a role as adipokine ([@bib21]), chemokine ([@bib22]) and a growth factor ([@bib23]). Although the different pathways are intertwined, chemerin's implication in inflammatory processes seems particularly attractive. Inflammation-related adipokines in general have been suggested to pose a link between excess fat mass, adipose tissue inflammation and chronic diseases and chemerin could therefore play a prominent role in this regard. In line with previous research, we observed higher chemerin concentrations in obese participants as compared to non-obese ([@bib24]). Expectedly, chemerin concentrations were also positively correlated with BMI and WC independent of participants' age and sex.

Correlation of circulating chemerin levels with markers of low-grade chronic inflammation, such as CRP ([@bib24]), further hint at chemerin's involvement in inflammatory pathways. In addition to CRP and going beyond what has been shown in humans so far, we showed positive associations with the inflammation-related adipokines FABP-4 and progranulin. Similar to chemerin, these biomarkers were shown to exhibit elevated circulating concentrations in obesity, but also to represent activated immune response due to infection and inflammation ([@bib25], [@bib26]) and act in a pro-inflammatory fashion ([@bib27], [@bib28]). Importantly, FABP-4 and progranulin were independent predictors of chemerin concentrations even beyond BMI, WC and CRP. These data potentially uncover an important interrelation between inflammation-related adipokines that deserve further exploration and careful interpretation. Revealed correlations both with obesity and inflammatory biomarkers essentially add to the growing body of evidence implicating chemerin as a biomarker linking immunity and metabolism in relation to chronic disease risk and point to pathways implicated in adipokine production beyond adiposity *per se*.

Our study has several strengths. The study population was reasonably large for a validation sample and included both sexes in acceptable proportions. However, the used study population does not allow an unconditional generalization of our results due to specific ethnicity, age range and apparent healthiness of the participants. Future studies should therefore take into account any differences in assays, laboratories, sample types, storage time, repeated samplings and timing of blood draw. However, regarding the last point, timing of blood draw in this study was preferably conducted in the morning, with only few exceptions. In addition, we explored the potential effect of time of the day at blood draw and found no influence.

In summary, we found chemerin to be a reliable biomarker potentially linking immunity and metabolism. This supports the conduct of prospective studies to further the understanding of chemerin's role in the development of chronic diseases.
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[^1]: Values are expressed as arithmetic means ([s.d.]{.smallcaps}), medians (25th, 75th percentile) or percentages. ^B^Reduced number of participants due to insufficient serum volume.

[^2]: FABP-4, fatty acid-binding protein-4; hsCRP, high-sensitivity C-reactive protein; MCP-1, monocyte chemoattractant protein 1.

[^3]: Paired two-sided *t*-test to compare concentrations between first and second measurement. ^B^Unpaired two-sided *t*-test to compare concentrations between strata for sex, age, waist circumference and hsCRP levels. ^C^ICC defined as ratio of between-person variance and total variance. ^D^Median hsCRP concentration = 1.27 μg/mL, reduced number of participants due to insufficient serum volume.
